// App-Quantinova.ai

5510 : Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

Researchers

Presenter

  • Antoine Italiano

Principal Investigators

  • Hans Prenen

  • Eva M. Guerra

  • Diego Tosi

  • Ruth Perets

  • Iwona Lugowska

  • Vladimir Moiseenko

  • Mahmut Gumus

  • Cagatay Arslan

  • Colin R. Lindsay

  • Muriel Richard

  • David Dejardin

  • Christophe Boetsch

  • Anton Kraxner

  • Stefan Evers

  • Taner Vardar

  • Nino Keshelava

  • Volker Teichgrber

  • Rafal Dziadziuszko

Medical Centers

  • Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France

  • Gustave Roussy Cancer Campus, Department of Drug Development (DITEP), Villejuif, France

  • Digestive Oncology Unit, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Biometrics Department, Institut du Cancer Montpellier, Montpellier, France

  • Rambam Health Care Campus, Haifa, Israel

  • Oddzial Badan Wczesnych Faz, Warsaw, Poland

  • Saint-Petersburg Scientific Practical Center for Specialized Medical Care, Saint-Petersburg, Russian Federation

  • Kartal Research and Training Hospital, Istanbul, Turkey

  • Medical Oncology Department, Izmir University, Medicine Faculty Hospital, Izmir, Turkey

  • Division of Cancer Sciences, University of Manchester, Manchester, UK., Manchester, United Kingdom

  • Roche, Translational Medicine, Schlieren, Switzerland

  • Roche, Biostatistics Oncology pRED, Basel, Switzerland

  • Roche Innovation Center Basel, Basel, Switzerland

  • Roche/Genentech, Basel, Switzerland

  • Roche Glycart AG, Schlieren, Switzerland

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Medical University of Gdansk, Oncology and Radiotherapy, Gdansk, Poland

Locations

  • France

  • Belgium

  • Spain

  • Israel

  • Poland

  • Russia

  • Turkey

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma

  • Cervical cancer

  • Solid malignancies

Biomarkers

  • Serpin B3

Drug/Treatment

  • Atezolizumab

  • Interleukin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03386721

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved